D.B.Y. Fontein

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial

D.B.Y. Fontein, Ayoub Charehbili, J.W.R. Nortier et al. · European Journal of Cancer · 2014 · 85 citations

Endocrine Oncology, Breast Oncology, Oncology +8

Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis

D.B.Y. Fontein, Caroline Seynaeve, Peyman Hadji et al. · Journal of Clinical Oncology · 2013 · 71 citations

Aortic Elasticity and Left Ventricular Function after Arterial Switch Operation: MR Imaging—Initial Experience

Heynric B. Grotenhuis, Jaap Ottenkamp, D.B.Y. Fontein et al. · Radiology · 2008 · 64 citations

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study

Johanna G. H. van Nes, D.B.Y. Fontein, E.T.M. Hille et al. · Breast Cancer Research and Treatment · 2012 · 60 citations · Full text

High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial

D.B.Y. Fontein, J.W.R. Nortier, Gerrit‐Jan Liefers et al. · European Journal of Surgical Oncology · 2011 · 51 citations · Full text

Pharmacology, Pharmacotherapy, Medicine +3